Biocytogen

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world

Preclinical services,animal models,gene targeting,humanized immune-oncology checkpoint mouse,immune-deficient mouse model,antibody research and development,animal production and breeding,in vivo study,fully human antibody mouse,immuno-oncology,antibody discovery,preclinical cro,pharmacology,and antibody licensing

Biocytogen operates in the Biotechnology research industry.

Biocytogen's revenue is 11m - 100m

Biocytogen has 51 - 200 employees.